Tiantan bio
Tiantan bio diagnostic supplies and other biological products
Tiantan Bio is a vaccine reagent developer, focusing on the research and production of vaccines, blood preparations, diagnostic supplies and other biological products, mainly to provide users with hepatitis B vaccine, polio vaccine, MMR vaccine, influenza vaccine, chickenpox vaccine and other products, its own Changchun Chijian Biological Products Co.
Innovative Drug Developer Rezu Bio Raised CNY 10 Mn in Series Pre-A
ForLong Biotech Nets Over CNY 100 Mn in Series A
CytoCan Corp. Nets CNY 10 Mn in Seed Round
Levostar Completes Pre-A Financing Round to Further Invest in CGT
BlissBio Nets Over CNY 100 Mn in Series B+
Weiyou Gene Nets Tens of Millions of CNY in Series Pre-A Round
NaviSeed Nets Tens of millions of CNY in Angel Round
Nuwacell Nets Hundreds of Mns of CNY in Series A
Cellatopia Secures Nearly CNY Ten Mn in Seed Funding
EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).
Apr 18, 2024 01:25 PM
Haier Biomedical 'Smart Blood City Network' Lands in Brazil
Brazil, as the largest country and economy in South America, faces numerous challenges brought about by an aging population. With the country's economy continuing to grow, healthcare issues are receiving increasing attention, and the demand for medical services is rising year by year.
Apr 15, 2024 03:45 PM
Enitiatebio Nets One Hundred Million of CNY in Series A Round
D3 Bio Completes A+ Round Financing, Accelerates Development of Product Pipeline
EqualOcean has learned that on April 8, 2024, D3 Bio(德昇济医药), a biotechnology company focused on the development and commercialization of innovative cancer and immune precision therapies, announced the successful completion of its A+ round financing led by Medicxi, a prominent European life sciences investment firm. The financing amounted to USD 62 million, with existing investor, Matrix Partners(经纬创投), also participating.
Apr 12, 2024 06:05 PM
Five departments including the central bank: encourage financial institutions to incorporate the application of open source technology into their informatization development plans